It looks increasingly likely that Roche’s cancer blockbuster Rituxan (rituximab) will face competition from a cheaper biosimilar in the coming months after backing from an FDA expert committee. Advisers to the FDA, sitting on its Oncologic Drugs A...
Original Article: Celltrion/Teva Rituxan biosimilar edges closer to US approval